Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Eli Lilly followed with Zepbound in November 2023
The interplay with glucose in proliferating cells
PubMed Clayton, A.H., Kingsberg, S.A., Goldstein, I., Baskin, L., Kim, N.N., Volkmann, E.R., Simon, J.A., Higgins, K.S., Jordan, R., & Portman, D.J
In the semaglutide arm only, other non-prespecified baseline variables (age, ethnicity, diabetes status, sex, type of surgery, time since surgery (months), meal-stimulated change in GLP-1 at baseline, postoperative %WL (from DOS to randomization)) and maximum %WL achieved after surgery or MBS response (weight regain versus suboptimal post-surgery weight loss) were added to the primary outcome linear regression model for the semaglutide arm only (therefore omitting the treatment allocation covariate) to assess their relationship with %WL induced by semaglutide at 68 weeks
